The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Tumor Immune Checkpoint Inhibitor Therapy Market Research Report 2025

Global Tumor Immune Checkpoint Inhibitor Therapy Market Research Report 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1765620

No of Pages : 97

Ask Your Query

Synopsis
Immune checkpoint inhibitors are some monoclonal antibody drugs developed for the corresponding immune checkpoints. inhibition

Global Tumor Immune Checkpoint Inhibitor Therapy market is projected to reach US$ 91520 million in 2029, increasing from US$ 53400 million in 2022, with the CAGR of 8.0% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Tumor Immune Checkpoint Inhibitor Therapy market research.

Key manufacturers engaged in the Tumor Immune Checkpoint Inhibitor Therapy industry include AstraZeneca, Bristol-Myers Squibb, Roche Holdings AG, Novartis AG, Pfizer, Sanofi, Merck, Ono Pharmaceutical and Regeneron, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.

When refers to consumption region, % volume of Tumor Immune Checkpoint Inhibitor Therapy were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Tumor Immune Checkpoint Inhibitor Therapy market and estimated to attract more attentions from industry insiders and investors.

Report Scope

This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Tumor Immune Checkpoint Inhibitor Therapy market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

By Company

  • AstraZeneca
  • Bristol-Myers Squibb
  • Roche Holdings AG
  • Novartis AG
  • Pfizer
  • Sanofi
  • Merck
  • Ono Pharmaceutical
  • Regeneron
  • Innovent

Segment by Type

  • PD-1/PD-L1
  • CTLA-4

Segment by Application

  • Hospital
  • Clinic
  • Other

Consumption by Region

  • North America (United States, Canada)
  • Europe (Germany, France, U.K., Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
  • Latin America (Mexico, Brazil, Argentina)
  • Middle East & Africa (Turkey, Saudi Arabia, UAE)

The Tumor Immune Checkpoint Inhibitor Therapy report covers below items:

Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source

Index

1 Tumor Immune Checkpoint Inhibitor Therapy Market Overview
1.1 Product Overview and Scope of Tumor Immune Checkpoint Inhibitor Therapy
1.2 Tumor Immune Checkpoint Inhibitor Therapy Segment by Type
1.2.1 Global Tumor Immune Checkpoint Inhibitor Therapy Market Value Comparison by Type (2023-2029)
1.2.2 PD-1/PD-L1
1.2.3 CTLA-4
1.3 Tumor Immune Checkpoint Inhibitor Therapy Segment by Application
1.3.1 Global Tumor Immune Checkpoint Inhibitor Therapy Market Value by Application: (2023-2029)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Global Tumor Immune Checkpoint Inhibitor Therapy Market Size Estimates and Forecasts
1.4.1 Global Tumor Immune Checkpoint Inhibitor Therapy Revenue 2018-2029
1.4.2 Global Tumor Immune Checkpoint Inhibitor Therapy Sales 2018-2029
1.4.3 Global Tumor Immune Checkpoint Inhibitor Therapy Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Tumor Immune Checkpoint Inhibitor Therapy Market Competition by Manufacturers
2.1 Global Tumor Immune Checkpoint Inhibitor Therapy Sales Market Share by Manufacturers (2018-2023)
2.2 Global Tumor Immune Checkpoint Inhibitor Therapy Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Tumor Immune Checkpoint Inhibitor Therapy Average Price by Manufacturers (2018-2023)
2.4 Global Tumor Immune Checkpoint Inhibitor Therapy Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Tumor Immune Checkpoint Inhibitor Therapy, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Tumor Immune Checkpoint Inhibitor Therapy, Product Type & Application
2.7 Tumor Immune Checkpoint Inhibitor Therapy Market Competitive Situation and Trends
2.7.1 Tumor Immune Checkpoint Inhibitor Therapy Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Tumor Immune Checkpoint Inhibitor Therapy Players Market Share by Revenue
2.7.3 Global Tumor Immune Checkpoint Inhibitor Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Tumor Immune Checkpoint Inhibitor Therapy Retrospective Market Scenario by Region
3.1 Global Tumor Immune Checkpoint Inhibitor Therapy Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Tumor Immune Checkpoint Inhibitor Therapy Global Tumor Immune Checkpoint Inhibitor Therapy Sales by Region: 2018-2029
3.2.1 Global Tumor Immune Checkpoint Inhibitor Therapy Sales by Region: 2018-2023
3.2.2 Global Tumor Immune Checkpoint Inhibitor Therapy Sales by Region: 2024-2029
3.3 Global Tumor Immune Checkpoint Inhibitor Therapy Global Tumor Immune Checkpoint Inhibitor Therapy Revenue by Region: 2018-2029
3.3.1 Global Tumor Immune Checkpoint Inhibitor Therapy Revenue by Region: 2018-2023
3.3.2 Global Tumor Immune Checkpoint Inhibitor Therapy Revenue by Region: 2024-2029
3.4 North America Tumor Immune Checkpoint Inhibitor Therapy Market Facts & Figures by Country
3.4.1 North America Tumor Immune Checkpoint Inhibitor Therapy Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Tumor Immune Checkpoint Inhibitor Therapy Sales by Country (2018-2029)
3.4.3 North America Tumor Immune Checkpoint Inhibitor Therapy Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Tumor Immune Checkpoint Inhibitor Therapy Market Facts & Figures by Country
3.5.1 Europe Tumor Immune Checkpoint Inhibitor Therapy Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Tumor Immune Checkpoint Inhibitor Therapy Sales by Country (2018-2029)
3.5.3 Europe Tumor Immune Checkpoint Inhibitor Therapy Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Tumor Immune Checkpoint Inhibitor Therapy Market Facts & Figures by Country
3.6.1 Asia Pacific Tumor Immune Checkpoint Inhibitor Therapy Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Tumor Immune Checkpoint Inhibitor Therapy Sales by Country (2018-2029)
3.6.3 Asia Pacific Tumor Immune Checkpoint Inhibitor Therapy Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Tumor Immune Checkpoint Inhibitor Therapy Market Facts & Figures by Country
3.7.1 Latin America Tumor Immune Checkpoint Inhibitor Therapy Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Tumor Immune Checkpoint Inhibitor Therapy Sales by Country (2018-2029)
3.7.3 Latin America Tumor Immune Checkpoint Inhibitor Therapy Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Tumor Immune Checkpoint Inhibitor Therapy Market Facts & Figures by Country
3.8.1 Middle East and Africa Tumor Immune Checkpoint Inhibitor Therapy Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Tumor Immune Checkpoint Inhibitor Therapy Sales by Country (2018-2029)
3.8.3 Middle East and Africa Tumor Immune Checkpoint Inhibitor Therapy Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Tumor Immune Checkpoint Inhibitor Therapy Sales by Type (2018-2029)
4.1.1 Global Tumor Immune Checkpoint Inhibitor Therapy Sales by Type (2018-2023)
4.1.2 Global Tumor Immune Checkpoint Inhibitor Therapy Sales by Type (2024-2029)
4.1.3 Global Tumor Immune Checkpoint Inhibitor Therapy Sales Market Share by Type (2018-2029)
4.2 Global Tumor Immune Checkpoint Inhibitor Therapy Revenue by Type (2018-2029)
4.2.1 Global Tumor Immune Checkpoint Inhibitor Therapy Revenue by Type (2018-2023)
4.2.2 Global Tumor Immune Checkpoint Inhibitor Therapy Revenue by Type (2024-2029)
4.2.3 Global Tumor Immune Checkpoint Inhibitor Therapy Revenue Market Share by Type (2018-2029)
4.3 Global Tumor Immune Checkpoint Inhibitor Therapy Price by Type (2018-2029)
5 Segment by Application
5.1 Global Tumor Immune Checkpoint Inhibitor Therapy Sales by Application (2018-2029)
5.1.1 Global Tumor Immune Checkpoint Inhibitor Therapy Sales by Application (2018-2023)
5.1.2 Global Tumor Immune Checkpoint Inhibitor Therapy Sales by Application (2024-2029)
5.1.3 Global Tumor Immune Checkpoint Inhibitor Therapy Sales Market Share by Application (2018-2029)
5.2 Global Tumor Immune Checkpoint Inhibitor Therapy Revenue by Application (2018-2029)
5.2.1 Global Tumor Immune Checkpoint Inhibitor Therapy Revenue by Application (2018-2023)
5.2.2 Global Tumor Immune Checkpoint Inhibitor Therapy Revenue by Application (2024-2029)
5.2.3 Global Tumor Immune Checkpoint Inhibitor Therapy Revenue Market Share by Application (2018-2029)
5.3 Global Tumor Immune Checkpoint Inhibitor Therapy Price by Application (2018-2029)
6 Key Companies Profiled
6.1 AstraZeneca
6.1.1 AstraZeneca Corporation Information
6.1.2 AstraZeneca Description and Business Overview
6.1.3 AstraZeneca Tumor Immune Checkpoint Inhibitor Therapy Sales, Revenue and Gross Margin (2018-2023)
6.1.4 AstraZeneca Tumor Immune Checkpoint Inhibitor Therapy Product Portfolio
6.1.5 AstraZeneca Recent Developments/Updates
6.2 Bristol-Myers Squibb
6.2.1 Bristol-Myers Squibb Corporation Information
6.2.2 Bristol-Myers Squibb Description and Business Overview
6.2.3 Bristol-Myers Squibb Tumor Immune Checkpoint Inhibitor Therapy Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Bristol-Myers Squibb Tumor Immune Checkpoint Inhibitor Therapy Product Portfolio
6.2.5 Bristol-Myers Squibb Recent Developments/Updates
6.3 Roche Holdings AG
6.3.1 Roche Holdings AG Corporation Information
6.3.2 Roche Holdings AG Description and Business Overview
6.3.3 Roche Holdings AG Tumor Immune Checkpoint Inhibitor Therapy Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Roche Holdings AG Tumor Immune Checkpoint Inhibitor Therapy Product Portfolio
6.3.5 Roche Holdings AG Recent Developments/Updates
6.4 Novartis AG
6.4.1 Novartis AG Corporation Information
6.4.2 Novartis AG Description and Business Overview
6.4.3 Novartis AG Tumor Immune Checkpoint Inhibitor Therapy Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Novartis AG Tumor Immune Checkpoint Inhibitor Therapy Product Portfolio
6.4.5 Novartis AG Recent Developments/Updates
6.5 Pfizer
6.5.1 Pfizer Corporation Information
6.5.2 Pfizer Description and Business Overview
6.5.3 Pfizer Tumor Immune Checkpoint Inhibitor Therapy Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Pfizer Tumor Immune Checkpoint Inhibitor Therapy Product Portfolio
6.5.5 Pfizer Recent Developments/Updates
6.6 Sanofi
6.6.1 Sanofi Corporation Information
6.6.2 Sanofi Description and Business Overview
6.6.3 Sanofi Tumor Immune Checkpoint Inhibitor Therapy Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Sanofi Tumor Immune Checkpoint Inhibitor Therapy Product Portfolio
6.6.5 Sanofi Recent Developments/Updates
6.7 Merck
6.6.1 Merck Corporation Information
6.6.2 Merck Description and Business Overview
6.6.3 Merck Tumor Immune Checkpoint Inhibitor Therapy Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Merck Tumor Immune Checkpoint Inhibitor Therapy Product Portfolio
6.7.5 Merck Recent Developments/Updates
6.8 Ono Pharmaceutical
6.8.1 Ono Pharmaceutical Corporation Information
6.8.2 Ono Pharmaceutical Description and Business Overview
6.8.3 Ono Pharmaceutical Tumor Immune Checkpoint Inhibitor Therapy Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Ono Pharmaceutical Tumor Immune Checkpoint Inhibitor Therapy Product Portfolio
6.8.5 Ono Pharmaceutical Recent Developments/Updates
6.9 Regeneron
6.9.1 Regeneron Corporation Information
6.9.2 Regeneron Description and Business Overview
6.9.3 Regeneron Tumor Immune Checkpoint Inhibitor Therapy Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Regeneron Tumor Immune Checkpoint Inhibitor Therapy Product Portfolio
6.9.5 Regeneron Recent Developments/Updates
6.10 Innovent
6.10.1 Innovent Corporation Information
6.10.2 Innovent Description and Business Overview
6.10.3 Innovent Tumor Immune Checkpoint Inhibitor Therapy Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Innovent Tumor Immune Checkpoint Inhibitor Therapy Product Portfolio
6.10.5 Innovent Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Tumor Immune Checkpoint Inhibitor Therapy Industry Chain Analysis
7.2 Tumor Immune Checkpoint Inhibitor Therapy Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Tumor Immune Checkpoint Inhibitor Therapy Production Mode & Process
7.4 Tumor Immune Checkpoint Inhibitor Therapy Sales and Marketing
7.4.1 Tumor Immune Checkpoint Inhibitor Therapy Sales Channels
7.4.2 Tumor Immune Checkpoint Inhibitor Therapy Distributors
7.5 Tumor Immune Checkpoint Inhibitor Therapy Customers
8 Tumor Immune Checkpoint Inhibitor Therapy Market Dynamics
8.1 Tumor Immune Checkpoint Inhibitor Therapy Industry Trends
8.2 Tumor Immune Checkpoint Inhibitor Therapy Market Drivers
8.3 Tumor Immune Checkpoint Inhibitor Therapy Market Challenges
8.4 Tumor Immune Checkpoint Inhibitor Therapy Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock